CB2 Insights Closes Oversubscribed Private Placement
February 22, 2019 11:40 ET
|
CB2 Insights
Medical Cannabis Clinical Data Company Raises in Excess of C$5M led by Merida Capital Partners TORONTO, Feb. 22, 2019 (GLOBE NEWSWIRE) -- MVC Technologies Inc., operating as CB2 Insights (“CB2” or...
Aleafia, Serruya Family Extend Exclusivity Period for Retail and Brand Joint-Venture
October 10, 2018 07:05 ET
|
Aleafia Health Inc.
TORONTO, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSXV: ALEF; OTCQX: ALEAF, FRA: ARAH) (“Aleafia”) or (the “Company”), has extended the exclusivity period for the proposed adult-use...
MVC Technologies Announces Rebrand to CB2 Insights with New Focus on Predictive Analytics for the Cannabis Industry
October 03, 2018 08:00 ET
|
CB2 Insights
TORONTO, Oct. 03, 2018 (GLOBE NEWSWIRE) -- MVC Technologies Inc. (“MVC”) today announced that it will undergo a significant brand transformation with the introduction of a corporate rebrand and a...
MVC Technologies Acquires Consumer Engagement and Loyalty Platform Developed for Global Cannabis Retailers
September 26, 2018 08:00 ET
|
MVC Technologies
TORONTO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- MVC Technologies Inc. (“MVC”), a leading cannabis-focused technology and services company, today announced that it has acquired customer loyalty,...
GB Sciences reports first quarter revenue of $1.3 million with gross profit of $700 thousand compared to revenue of $69,100 for same period last year
August 15, 2018 08:50 ET
|
GB Sciences, Inc.
Las Vegas, NV, Aug. 15, 2018 (GLOBE NEWSWIRE) -- For the three months that ended June 30, 2018, GB Sciences, Inc. (OTCQB: GBLX) reported revenue of $1,315,284 and gross profit of $734,719. This...
GB Sciences Strengthen Their Current and Future Compliance Programs by Building A Relationship with Adherence Compliance
July 31, 2018 05:30 ET
|
GB Sciences, Inc.
Las Vegas, NV, July 31, 2018 (GLOBE NEWSWIRE) -- GB Sciences, Inc (OTCQB:GBLX) has contracted Adherence Compliance, a leading cannabis compliance software and services firm, for its Chief Compliance...
GB Sciences Files Patent on Cannabis-based Therapies for the Treatment of Asthma, Urinary Cystitis, Hearing Loss, plus Chronic, Inflammatory and Neuropathic Pain
June 27, 2018 05:30 ET
|
GB Sciences, Inc.
Las Vegas, June 27, 2018 (GLOBE NEWSWIRE) -- GB Sciences, Inc. (OTCQB: GBLX) has filed a new provisional patent application on the use of cannabis-based therapies for the manipulation of...